Pfizer Inc. (NYSE:PFE) Shares Sold by Royal Capital Wealth Management LLC

Royal Capital Wealth Management LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 25.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 6,675 shares of the biopharmaceutical company’s stock after selling 2,300 shares during the period. Royal Capital Wealth Management LLC’s holdings in Pfizer were worth $221,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Financial Gravity Asset Management Inc. lifted its holdings in shares of Pfizer by 559.2% during the 2nd quarter. Financial Gravity Asset Management Inc. now owns 501 shares of the biopharmaceutical company’s stock worth $14,919,000 after acquiring an additional 425 shares during the period. Worth Asset Management LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new stake in Pfizer during the 3rd quarter worth approximately $30,000. Sanctuary Wealth Management L.L.C. acquired a new stake in Pfizer during the 4th quarter worth approximately $50,000. Finally, Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the 3rd quarter worth approximately $34,000. 68.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 3,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average price of $26.47 per share, with a total value of $79,410.00. Following the purchase, the director now owns 9,000 shares of the company’s stock, valued at approximately $238,230. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PFE. Truist Financial dropped their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Barclays reduced their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Friday. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $36.88.

Get Our Latest Analysis on PFE

Pfizer Stock Performance

Shares of PFE traded up $0.01 during trading hours on Friday, reaching $26.57. 23,554,184 shares of the company’s stock traded hands, compared to its average volume of 41,863,543. The firm has a market capitalization of $150.03 billion, a price-to-earnings ratio of 73.86, a P/E/G ratio of 1.21 and a beta of 0.62. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a twelve month low of $25.76 and a twelve month high of $42.22. The business’s fifty day simple moving average is $28.00 and its two-hundred day simple moving average is $30.61.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. Analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, January 26th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, January 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.32%. This is a boost from Pfizer’s previous quarterly dividend of $0.41. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.